Genentech to expand California biologics manufacturing facilities

Published: 14-Oct-2013
Manufacturing Finance Pharmaceutical

Investment of $285m will create more than 250 new jobs


Genentech, a member of the Roche Group, is to invest more than US$285m in an expansion of its biologics manufacturing facilities in Vacaville and Oceanside, California.

The company’s US manufacturing network spans three locations in California – South San Francisco, Vacaville, and Oceanside – and Hillsboro, Oregon. When the expansion is complete, Genentech’s Vacaville facility will not only be the largest producer of biologic medicines for the Roche Group but also the largest biotech manufacturing facility in the world.

'This investment and expansion will result in the addition of more than 250 new jobs at the Vacaville and Oceanside facilities over the next four years, bringing the total number of Genentech manufacturing jobs in California to close to 3,000,' said Ian Clark, Chief Executive Officer of Genentech. 'California has always had an impressive skilled workforce that has allowed Genentech to hire diverse and talented individuals in various disciplines,' he added.

  • Companies:
  • Genentech
  • Roche Group
See more

You may also like

Regulatory

Roche's breast cancer combination therapy Itovebi bags FDA approval

Read more
Itovebi plus palbociclib and fulvestrant reduced the risk of disease progression or death significantly in patients

Trending Articles

  1. Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
  2. Dual-chamber packaging systems as a simplification factor in the supply chain Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
  3. Sanofi invests €40m into biopharmaceutical manufacturing at its Lyon Gerland site The pharma giant has expanded its French monoclonal antibody production capabilities, while also dedicating €25m to the development of a second-gen polyclonal antibody
  4. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  5. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Regulatory

Roche's breast cancer combination therapy Itovebi bags FDA approval

Itovebi plus palbociclib and fulvestrant reduced the risk of disease progression or death significantly in patients
Finance

Lonza completes acquisition of large-scale biologics site in Vacaville (US) from Roche

Acquisition extends Lonza’s US Biologics footprint with a significant presence on the West Coast, complementing its existing global manufacturing network
Research & Development

Roche's antiviral Xofluza reduces flu transmission in Phase III trial

Topline results suggest that Xofluza could be used to reduce the transmission of seasonal influenza
Regulatory

Roche receives approval for PiaSky to treat patients with PNH in Europe

The subcutaneous C5 inhibitor stops the patients from having to attend the clinic to receive IV infusions for PNH management
Pharmaceutical

Pharma giants Roche and Novartis top worldwide reputation poll

The report examined the reputations of the 34 biggest pharmaceutical companies globally, including GSK, Novartis, Pfizer, Moderna and Johnson & Johnson
Finance

Swiss medtech investment surpasses last year, biotech run rates are up

Fuelled by innovation, Swiss medtech investment already surpasses last year, while biotech run rates are up
Finance

Lead Pharma enters research collaboration with Roche

Under the terms of the agreement, Lead Pharma will receive an upfront payment of $8.44m
Subscribe now